Summary: As quercetin, which can inhibit phosphatidylinositol 3-kinase, nuclear factor-kappa B, and protein kinase C (PKC) pathways, induced expression of natural killer group 2, member D (NKG2D) ligands on cancer cells and made the cells sensitive to NK -cell-mediated killing; inhibition of epidermal growth factor receptor (EGFR) pathway might lead to induction of NKG2D ligands. In this study, it was investigated whether EGFR inhibitors, including erlotinib or gefitinib, could regulate expression of NKG2D ligands in various lung cancer cells including A549, NCI-H23, and SW-900. The EGFR inhibitors predominantly increased transcription and surface expression of ULBP1, and subsequently increased susceptibility of the cancer cells to NK-92 cells. When the selective inhibitors of nuclear factor-kappa B, phosphatidylinositol 3-kinase, mitogen-activated protein kinases, and PKC were treated to discriminate downstream signaling of EGFR pathway, expression of ULBP1 in the cancer cells was induced by inhibition of PKC. Treatment with phorbol 12-myristate 13-acetate restored the EGFR inhibitor-induced ULBP1 transcription. Binding activity to ULBP1 promoter region of AP-2a, which suggested as suppressor of expression of ULBP1, was decreased by treatment with EGFR inhibitors, and restored by pretreatment with phorbol 12-myristate 13-acetate in A549 and SW-900. Rottlerin, a PKCd inhibitor, also decreased the binding activity of AP-2a in dose-dependent manner. This study suggests that EGFR inhibitors enhanced the susceptibility to NK cellmediated lysis of lung cancer cells by induction of ULBP1 by inhibition of PKC pathway and therapeutic efficacy of EGFR inhibitors in lung cancer may be mediated in part by increased susceptibility to NK cell-mediated cytotoxicity.
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Key Words: NKG2D ligands, lung cancer, EGFR inhibitors (J Immunother 2011;34:372-381) L ung cancer is the most commonly diagnosed cancer in the world and a leading cause of cancer death. Unfortunately, lung cancer is hard to cure due to high recurrence rate and metastasis. A number of clinical trials of natural killer (NK) cell-based immunotherapy have been performed in leukemia, lymphoma, and hematopoietic stem cell transplantation, and showed benefit with reduced diseases and lower relapse rate. [1] [2] [3] [4] NK cells are particularly efficient at eliminating metastatic cells, which generally lack expression of some or all self major histocompatibility complex (MHC) class I molecules, a phenomenon referred to as "missing-self" recognition [5] [6] [7] [8] [9] and chemotherapyresistant cancer cells are more susceptible to NK cells. 10 NK cells can kill many different mouse and human tumor cell lines in vitro, and freshly isolated human cancer cells and their cytotoxicity is controlled by balance of signaling through activating and inhibitory receptors. 11 An activating receptor NKG2D (natural killer group 2, member D) is expressed on human NK cells, CD8
+ T lymphocytes and gd T lymphocytes 7, 12 and it has been known that the binding of NKG2D to its ligands may activate NK and T cells, and promote cytotoxic lysis of the target cells. 13 Eight distinct NKG2D ligands in humans (MHC class I chain-related gene A (MICA), MICB, UL16-binding protein (ULBP) 1 to 6 (RAET1I,H,N,E,G,L) were described until now. 14 Although it have been reported that MIC and ULBPs can be expressed also on normal hematopoietic cells, including bone marrow cells and mature dendritic cells, it has been generally accepted that expression of NKG2D ligands is mostly restricted to transformed, infected, and stressed cells, and generate the immune responses of NKG2D expressing immune cells. 15, 16 NKG2D ligands may play a key role in the recognition of transformed cells by the immune system and represent a promising therapeutic target for evoking the immune response against cancer.
Many cancer cell lines and freshly isolated primary cancers from patient with hepatocellular carcinoma, glioblastoma, and different types of leukemia, express NKG2D ligands constitutively. [17] [18] [19] [20] Earlier studies have showed that expression of NKG2D ligands on cancer cells renders them susceptible to NK -cell-mediated lysis and rejects transplanted cancer cells. 21 Although NK cells are effective killers of most cancer cells in vitro, it is obvious that they do not effectively eliminate cancers in patients and strategies aimed at increasing both NK cell activation and cancer cell susceptibility to NK cells have been required to improve the NK -cell-based immunotherapy. The selective upregulation of NKG2D ligands on tumor cells is 1 attractive approach to increase the susceptibility to NK cells. Anticancer agents, including the DNA damage-inducing cisplatin and 5-fluorouracil, upregulate NKG2D ligands 22 and the histone deacetylase inhibitors, currently being evaluated in clinical trials, also upregulates NKG2D ligands on hepatocellular carcinoma cells. 23, 24 Moreover, Low-Dose bortezomib, a proteasome inhibitor, enhances expression of the human NKG2D ligands MICA and MICB. 25 However, it is known that conventional anticancer agents, which have been commonly used to treat cancer patients, have severe myelosuppressive side effect in patients 26, 27 and may be thought that they will reduce immune responses against cancer cells. It may be limited to use them in combination with NK cell-based immunotherapy. Recently, we demonstrated that quercetin, which has inhibitory activities against phosphatidylinositol 3-kinase (PI3-K), nuclear factor-k B (NF-kB), and protein kinase C (PKC) pathways, induced the expression of MICB, ULBP1, and ULBP2 in K562, SNU-1, and SNU-C4 cells, 28 and suggested that signaling block of these pathways may be associated with induction of the NKG2D ligands. Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is involved in development of non-small cell lung cancer and modulates a variety of downstream signaling pathways including NFkB, PI3-K, mitogen-activated protein kinases (MAPK), and PKC pathways. 29, 30 Therefore, EGFR-targeted therapies may induce NKG2D ligands expression by inhibition of the downstream pathways such as NF-kB, PI3-K, MAPK, and PKC pathways. As EGFR inhibitors such as erlotinib and gefitinib are proved to treat lung cancer without myelosuppressive side effect in patients, 31 -33 they will be attractive modalities that can be combined with NKbased immunotherapy. In this study, it was investigated whether EGFR inhibitors could modulate the expression of NKG2D ligands and enhance the susceptibility to NK cellmediated cytotoxicity.
MATERIALS AND METHODS

Cell Lines and Reagents
Three human lung cancer cell lines, which express EGFR, were used in this study including A549, NCI-H23, and SW-900. These cell lines were obtained from the Korean Cell Line Bank (Seoul, Korea) and were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY), 2 mM L-glutamine, 100 mg/mL streptomycin, and 100 U/mL penicillin. In cytotoxicity assay, the NK-92 cell line was obtained from American Type Culture Collection (Rockville, MD) and maintained in a-Minimum Essential Modified medium supplemented with 12.5% (v/v) fetal bovine serum, 12.5% (v/v) horse serum, 2 mM L-glutamine, 0.1 mM 2-mercaptoethanol, 200 U/mL of recombinant human interleukin-2, 100 mg/mL streptomycin, and 100 U/mL penicillin. All cell lines were cultured at 371C in a humidified atmosphere containing 5% CO 2 .
Recombinant human EGF was purchased from R&D systems, Inc. (Minneapolis, MN), and erlotinib and gefitinib were purchased from SELLECK chemicals (Houston, TX). LY294002 and Bay11-7082, which are inhibitor of PI3-K and NF-kB, respectively, were purchased from Calbiochem (Merck KGaA, Darmstadt, Germany). PD98059, U0126, and SB203580, which are inhibitors of MAPK, were purchased from Calbiochem (Merck KGaA, Darmstadt, Germany). BIM I (bis-indolyl maleimide I), Go¨6976, Rottlerin, and PMA (phorbol 12-myristate 13-acetate), which are modulators of PKC, were purchased from Sigma Chemical Company. All reagents were dissolved in dimethyl sulfoxide except EGF, which is dissolved with phosphate buffered saline, and dimethyl sulfoxide concentration in the culture medium was kept below 0.1%, which had no detectable effect on cell growth or viability.
Total RNA Extraction, Multiplex Reverse Transcription (RT)-Polymerase Chain Reaction (PCR), and Conventional PCR Total RNA extraction and multiplex RT-PCR were performed using 7 pairs of primer set as previously described. 34 In brief, total RNA was extracted using RNeasy Mini Kit (Qiagen GmbH, Germany) from cell lines following the manufacturer's protocol. One microgram of extracted total RNA was used to synthesize cDNA. Next, 100 pmol of random primers (Takara, Japan) and 100 U of M-MLV reverse transcriptase (Promega Co.) were added and incubated at 371C for 60 minutes. The resulting cDNA was used in the PCR reaction with QIAGEN Multiplex PCR Kit (Qiagen GmbH, Germany). Seven pairs of primer sets were used to investigate the expression of 5 NKG2D ligands including MICA/B and ULBP1/2/3, and 2 additional genes including b-actin and ribosomal protein L19 which were a loading control and degradation marker, respectively. PCR was performed using rTaq polymerase (Takara, Japan) and PTC-100 thermal cycler (MJ research, MA). The PCR products were analyzed using ethidium bromide-stained 2.0% agarose electrophoresis and quantitated by image analyzing software, Quantity-one (Bio-Rad Laboratories, Inc., Hercules, CA).
Real-time Quantitative PCR (qPCR)
2X Power SYBR Green PCR Master Mix (Applied Biosystems, UK), a ready-to-use cocktail containing all components except primers and template, was mixed with templates and 500 nM appropriate primers for real-time qPCR to analyze the quantity of templates. Distilled water was added to final reaction volume of 25 mL in 96-well PCR plate (Bio-Rad, Hercules, CA) and the plate was taped with PCR sealers (Bio-Rad, Hercules, CA). The amplification was performed using Bio-Rad iCycler thermal cycler (BioRad, Hercules, CA) as follows. After initial denaturation step at 951C for 10 minutes, templates were denatured at 951C for 30 seconds, primers were annealed at 581C for 30 seconds, and DNA extension was performed at 601C for 1 minutes (each cycle was repeated 60 times). The expression of target genes was compensated using the expression of b-actin and presented by the expression ratio between untreated control cells and treated cells.
Flow Cytometry
To determine the surface expression of the NKG2D ligands on cancer cells, the cells were incubated with NKG2D ligand-specific monoclonal antibodies (mAbs) including mouse anti-MICA and anti-MICB, mouse anti-ULBP1-3 (R&D system, Wiesbaden, Germany), and antihuman MHC class I molecules (Serotec, Oxford, UK) or the corresponding isotype controls at 10 mg/mL followed by incubation with the goat antimouse-PE conjugated (BD Phamingen, San Diego, CA). The analysis was performed on the FACS Sort (Becton Dickinson, Mountain View, CA) using CellQuest software (Becton Dickinson) and the cell surface expression was quantified by the value of the mean fluorescence intensities obtained with the specific mAbs.
NK Cell-mediated Cytotoxicity Assay
NK cell-mediated cytotoxicity was determined with the DELFIA EuTDA Cytotoxicity Reagents (PerkinElmer Life Sciences, MA). The precise procedure was described previously. 28 In brief, the target cells (1 Â10 6 cells/mL) were incubated with freshly prepared 10 mM of BATDA, an fluorescence enhancing ligand, in 2 mL culture medium for 30 minutes at 371C, washed 5 times with phosphate buffered saline and finally resuspended to 5 Â10 4 cells/mL in the culture medium. Next, 100 mL of BATDA-labeled target cells (5000 cells) were pipetted into a round-bottom sterile plate. These target cells were cocultured with NK-92 cells for 2 hours at an effector/target ratio ranging from 2.5:1 to 10:1. After incubation, 20 mL of the supernatant from each well was transferred to the wells of flat-bottom 96 well plates and 180 mL of the europium (Eu) solution were added to form a highly fluorescent and stable chelate (EuTDA). After the plates were rocked at room temperature for 15 minutes, the fluorescence of the EuTDA chelates was measured with time-resolved fluorometry (Victor3, PerkinElmer). The percent-specific release was calculated from (experimental release À spontaneous release)/(maximum release À spontaneous release) Â100 (%). In the blocking experiments, the blocking anti-NKG2D mAb (R&D system, Weisbaden, Germany) was added to suspension of the NK-92 cells at 20 mg/mL and incubated for 30 minutes before they cocultured with the target cells.
Chromatin Immunoprecipitation (ChiP) Assay
ChiP assay were performed by manufacture's protocols using EZ-ChiP (Millipore Corporation, Billerica, MA). Cultured cells were cross-linked with 1% formaldehyde and harvested. They were lysed with 130 mL lysis buffer containing 1 Â protease inhibitor cocktail II and the supernatant samples of lysates were divided by 50 mL per microfuge tube until use. The samples were fragmented to appropriate length of DNA in cold water using Bioruptor (COSMOBIO, Japan) for 30 minutes with optimized power. After removing insoluble material, add 450 mL of dilution buffer containing protease inhibitor cocktail II and add 50 mL of protein G agarose for each tubes. The tubes were incubated for 1 hour at 41C with rotation and agarose was pelleted by brief centrifugation (3000 to 5000 Â g for 1 min). Five microliter (1%) of the supernatants was collected as Inputs and saved at 41C. The supernatants were transferred to fresh microfuge tubes and 1 mg of the antibodies against AP-2a (Santa-Cruz Biotechnology, Inc., CA) was added to each tubes. After overnight incubation at 41C with rotation, 50 mL of protein G agarose were added to each immunopricipitates (IPs) and incubated for another 1 hour at 41C with rotation. Agarose was pelleted by brief centrifugation and washed by cold buffers. For DNA elution, 100 mL of elution buffer containing sodium dodecyl sulfate and NaHCO 3 were used and supernatants were collected. To reverse the DNA-Protein cross-link of IPs and Inputs, they were incubated with 8 mL 5 M NaCl for overnight at 651C. Then RNase A and protease K were treated at 371C for 30 minutes and at 451C for 1 to 2 hours, respectively. Each 100 mL DNA samples (IPs and Inputs) were purified with spin filter, and conventional or real-time PCR (qPCR) was performed to analyze the binding activity of AP-2a to ULBP1 promoter region using a primer set (forward-20 mer; ATGGAAGGAACGGAAGGAAC, reverse-19 mer; CGCTGCCATTGTAGACCTG).
Statistical Analysis
To evaluate the altered level of gene expression, the mean folder of gene expression in EGFR inhibitor treated cells compared with untreated control and standard error of the mean was calculated. For comparison of groups, the paired Student t test was performed. A P-value <0.05 was considered statistically significant in all experiments.
RESULTS
EGFR Inhibitors Regulate NKG2D Ligands Expression in Lung Cancer Cells
To analyze the mRNA expression of NKG2D ligands including MICA/B and ULBP1/2/3, multiplex RT-PCR analysis was performed in A549, NCI-H23, and SW-900 cells, which were treated with erlotinib or gefitinib at indicated concentration or for indicated time. Level of ULBP1 transcript was predominantly increased in A549, NCI-H23, and SW-900 cells (12.2±2.9**/6.9±0.3*, 4.0±1.3*/3.0±0.6*, 2.4±0.5*/2.5±0.2**, respectively; mean fold change ± standard error of specific mRNA levels in treated cancer cells compared with untreated control cells, *P<0.05, **P<0.01) treated with erlotinib or gefitinib at 18 hours, and level of MICA transcript was increased in gefitinib-treated NCI-H23 cells (1.7±0.1; P=0.014) (Fig. 1A) . There was nothing peculiar in change of other NKG2D ligands mRNA expression in all 3 lung cancer cells by treatment with EGFR inhibitors (P>0.05) (Figs. 1A, B) . However, treatment with EGF did not alter the expression of NKG2D ligands significantly in A549 and SW-900 cells (Fig. 1C) .
When cell surface proteins were analyzed by flow cytometry, ULBP1 protein was predominantly increased after the transcriptional induction. However, changes of some NKG2D ligand proteins were different from patterns of transcription and there were some discrepancies between mRNAs and surface proteins. MICA protein was decreased in erlotinib-treated A549 cells (P=0.0452). MICB proteins were increased in erlotinib and gefitinib-treated A549 and NCI-H23 cells, and in erlotinib-treated SW-900 cells (P<0.05). MICA proteins were increased in gefitinibtreated NCI-H23 cells according to the mRNA increase (P=0.0496). In all cell lines, there were only minimal changes of the surface expression of human MHC class I molecules (Fig. 2) .
Cytolytic Activity of NK Cells to Lung Cancer Cells is Enhanced After Treatment With EGFR Inhibitors
To investigate whether the induction of NKG2D ligand proteins increased the susceptibility of lung cancer cells to cytolytic activity of NK cells, cytotoxicity assay was performed using the DELFIA EuTDA cytotoxicity Reagents. After treatments with erlotinib and gefitinib for 24 hours, the treated and untreated control cells were cocultured with NK-92 cells and lysed cancer cells were measured by releasing BATDA in media. Susceptibility of lung cancer cells to cytolytic activity of NK cells was significantly increased by treatment with EGFR inhibitors and was reversed by blocking step using mAb against NKG2D before the assay in all lung cancer cells (Fig. 3) .
ULBP1 Expression is Regulated After Treatment With Inhibitors of EGFR Downstream Molecules
As ULBP1 was dominantly upregulated by EGFR inhibitors, we investigated to find which downstream molecules of EGFR involved in induction of ULBP1. A549 and SW-900 cells were treated with inhibitors of some EGFR downstream molecules such as which were NF-kB inhibitor (Bay11-7092), PI3-K inhibitors (Ly294002 and Wortmannin), and MAPK inhibitors (PD98059, SB203580, and U0126), and modulation of ULBP1 expression was analyzed using multiplex RT-PCR. The ULBP1 expression was not significantly upregulated after treatment with the inhibitors (Fig. 4A) . However, a pan-PKC inhibitor, BIM I, increased the expression of ULBP1 (Fig. 4B) . As PKC has several isozymes whose functions are different, we treated A549 and SW-900 cells with 2 selective isozyme-inhibitors, Go¨6976 and Rottlerin, which inhibit PKCa/b and PKCd, respectively. Rottlerin and Go¨6976 were predominant inducer of ULBP1 in A549 and SW-900 cells (5.2±1.2**/5.4±1.3* and 3.8±0.4*/3.5±0.4*, respectively; *P<0.05, **P<0.01). 
EGFR Inhibitor-induced ULBP1 Expression is Prevented by Treatment With PMA
As it was thought that PKC had a most important role in induction of ULBP1, it was investigated whether activation of PKC could suppress the ULBP1 expression by treatment with PMA using multiplex RT-PCR and Real-time qPCR. When lung cancer cells were treated with PMA alone or combined with EGFR inhibitors, PMA effectively prevented A549 and SW-900 cells from the induction of ULBP1 by EGFR inhibitors (Fig. 5) . PMA and EGFR inhibitors might have an opposing effect in ULBP1 expression through PKC pathway.
The Expression of ULBP1 is Regulated by Binding Activity of AP-2a by PKC Pathway
To determined transcription factor, which is regulated by PKC and increases the promoter activity of ULBP1, binding activity of AP-2a was investigated using ChiP assay. PMA and EGFR inhibitors profoundly regulated the binding activity of AP-2a with opposing effect each other and binding of AP-2a was negatively related with the expression of ULBP1 (Fig. 6A) . When A549 cells were treated with Rottlerin, induction of ULBP1 which was analyzed using multiplex RT-PCR might be related with decrease of binding activity of AP-2a to ULBP1 promoter in dose-dependent manner (Fig. 6B) . From these results, it was thought that the expression of ULBP1 might be regulated by AP-2a by PKC pathway.
DISCUSSION
NK cells can kill many different cancer cell lines in vitro, and freshly isolated cancer cells. As cytotoxicity of NK cells is controlled by balance of signaling through activating and inhibitory receptors, upregulation of NKG2D ligands in cancer cells is an attractive approach to activate NK cells and promote cytotoxic susceptibility of cancer cells to NK cells. 35 Recently, we demonstrated that signaling block of multiple pathways led to induction of the NKG2D ligands in various cancer cells including chronic myeloid leukemia, stomach and colon cancer cells. 28 As EGFR, which is overexpressed in many cancers, modulates a variety of downstream signaling pathways including NF-kB, PI3-K, MAPK, and PKC pathways, 29, 30 and can be targeted with monoclonal antibodies and small molecules in cancer patients, we investigated whether EGFRtargeted drugs would induce NKG2D ligands expression and enhance the susceptibility to NK cell-mediated cytotoxicity in this study.
MICA/B expression can be increased by a variety of stresses, such as heat shock, hydrogen peroxide, histone deacetylase inhibition, DNA damage agents, and viral or bacterial infection, 22, [36] [37] [38] [39] but their precise mechanisms remain unclear and controversial. It has been known that the essential transcription factors for the expression of To determine the specificity of NKG2D-mediated cytolysis of lung cancer cells, NK-92 cells were preincubated with blocking mAb against NKG2D before the assay (gray filled square and triangle) and corresponding isotype mAb (open square and triangle). All experiments were done in triplicate and significant difference between NK cell-mediated cytotoxicities against untreated and treated cells were presented. (*P < 0.05, **P < 0.01, ***P < 0.001). EGFR indicates epidermal growth factor receptor; mAb, monoclonal antibody; NKG2D, natural killer group 2, member D.
MICA/B are the ubiquitous Sp1, Sp3, and NF-Y (CBF), and the stress-inducible heat shock factor 1. [40] [41] [42] As EGF activates the Sp1/Sp3 transcription factors by MAPK activity, 43, 44 and activity of NF-Y is increased by Akt and Erk activity, [45] [46] [47] it was supposed that inhibition of EGFR would decrease MICA/B transcription. In contrast, other study reported that glycogen synthase kinase-3 activity, which was negatively regulated by EGF in retinal pigment epithelium and NIH-3T3 cells, 48, 49 is essential for the induction of MICA/B expression by treatment with inhibitors, 24 was supposing that EGFR inhibitors might increase MICA/B transcription. In our previous report (Ref. 26 ), transcription of MICA was decreased and MICB was increased by inhibition of PI3-K and NF-kB, and multiple signaling blocks by treatment with quercetin in K562 and SUN-C4 cells. However, in this study neither EGF nor EGFR inhibitors altered MICA/B transcription except that MICA transcription in NCI-H23 cells was increased by treatment with gefitinib. Therefore, the transcriptional regulation of MICA/B by EGFR pathway seemed to be more complex and remains to be elucidated by further study.
As, it has been reported that surface proteins of NKG2D ligands are regulated through many complex mechanisms of posttranscriptional and posttranslational steps, and the discrepancy between transcription and protein expression of NKG2D ligands have been frequently described, 36, 50, 51 it was necessary to measure the NKG2D ligands surface expression. In this study, the surface expression of MICA was not altered in gefitinib-treated A549, erlotinib-treated NCI-H23, and erlotinib and gefitinib-treated SW-900 cells, and was increased in gefitinibtreated NCI-H23, consistent with their transcriptional modulation. However, the surface expression of MICA was decreased without decrease of its transcription in erlotinib-treated A549 cells. It was reported that imatinib, a tyrosine kinase inhibitor targeting BCR-ABL oncoprotein in CML cells, decreased MICA surface protein without decrease of transcription by inhibition of PI3-K/mTOR and protein synthesis. 20 Therefore, the decreased MICA surface expression in erlotinib-treated A549 cells may result from inhibition of EGFR/PI3-K signaling. However, we do not understand why the surface expression of MICA was regulated differentially in A549, NCI-H23, and SW-900 cells after exposure to gefitinib and erlotinib.
On the contrary, after treatment with EGFR inhibitors, surface expression of MICB was increased without increase of MICB transcription in all lung cancer cell lines except gefitinib-treated SW-900 cells. These result suggested that regulation of MICB surface expression by treatment with EGFR inhibitors was mainly controlled by posttranscriptional steps. Although the reasons of increased MICB surface expression were not clear, it has been known that the surface expression of MICA/B is regulated by posttranscriptional steps such as microRNA binding to their transcripts, and surface protein shedding and proteasomal degradation of MICA/B. 20, [51] [52] [53] [54] [55] [56] Previously, it was reported that suppression of EGF-induced MAPK activity and AP-1 binding capacity decreased the expression of matrix metalloproteinases in fibroblast, 57 which may have a role in shedding of MICB, and inhibition of MAPKs signaling suppressed stability of microRNA-generating complex, which is consist of HIV TAR RNA-binding protein and Dicer, whose silencing upregulates MICA/B, 58, 59 and prevented the induction of atrogin1/MAFbx and E3 ubiquitin ligase in myocytes, 60, 61 which downregulates cell surface expression of MICA/B. 62 As EGFR inhibitors increased the surface expression of MICB, inhibition of EGFR might affect the various posttranscriptional steps of MICB expression by inhibition of downstream molecules. However, it was not understood which regulation mechanisms really have responsibility for induction of MICB and why the surface expression of MICA and MICB was regulated differentially in response to treatment with erlotinib and gefitinib in various lung cancer cells.
Treatment with EGFR inhibitors predominantly induced the expression of ULBP1 at mRNA and protein levels in all lung cancer cells, whereas treatment with EGF did not suppress ULBP1. As it has been known that ULBP1 is induced by H 2 O 2 by activation of MAPK signaling in normal healthy bronchial epithelial cells, 38 and transcription of ULBP1 and ULBP2 is increased by inhibition of PI3-K and NF-kB and restored by treatment with PMA in K562 cells, 28 we investigated which downstream molecules of EGFR including NF-kB, PI3-K, MAPK, and PKCs might be involved in the regulation of ULBP1 expression in lung cancer cells using selective inhibitors. In our study, expression of ULBP1 was dramatically increased by inhibition of PKC using BIM I, Go¨6976, and Rottlerin (inhibitors of pan-PKC, PKCa/b and PKCd, respectively). However, it was not significantly changed by inhibition of NF-kB, PI3-K, and MAPK in lung cancer cells, suggesting that the expression of ULBP1 could be regulated differentially between different cell types. Induction of ULBP1 by treatment with EGFR inhibitors was blocked by pretreatment of PMA in lung cancer cells. Therefore, it was supposed that PKC activity might have a crucial role on regulation of the ULBP1 transcription by EGFR inhibition. As both Rottlerin and Go¨6976 were potent inducers of ULBP1, activities of various PKC isozymes might contribute to ULBP1 expression in lung cancer cells. It was previously known that transcription of ULBP1 might be regulated positively by Sp1, Sp3, and NF-Y, and negatively by AP-2a. 41, 42, 63, 64 Although EGF activates the Sp1/Sp3 transcription factors by MAPK pathway, 43, 44 and the activity of Akt and Erk upregulates the activity of NF-Y, [45] [46] [47] ULBP1 transcription was induced by EGFR inhibitors not by EGF in this study, suggesting that transcription factors including Sp1/Sp3 and NF-Y may not be involved in induction of ULBP1 in lung cancer cells. Meanwhile, it has been known that AP-2a may bind to the ULBP1 promoter region and negatively regulate the promoter activity, 65 and its binding capacity is increased by PKC activation in monocytes. 66 Therefore, it could be suggested that AP-2a activity might be involved in EGFR inhibitor-induced ULBP1 expression in lung cancer cells. In this study, when AP-2a binding activity was investigated in A549 and SW-900 cells, it was suppressed by treatment of EGFR inhibitors and Rottlerin, and restored by pretreatment with PMA. Therefore, induction of ULBP1 by EGFR inhibitors was seemed to result from inhibition of PKC and subsequent decrease of AP-2a binding activity.
Finally, it was investigated whether erlotinib and gefitinib could increase susceptibility of lung cancer cells to NK cells. The susceptibility to NK-92 cells of 3 lung cancer cells could be enhanced by induction of NKG2D ligands after treatment with erlotinib and gefitinib. Erlotinib-treated A549 cells with increased MICB and ULBP1 proteins showed an increased susceptibility to NK cells despite decrease of MICA. These results suggested that susceptibility of lung cancer cells to NK cells was determined by integration of signals from a NKG2D receptor, which can bind to various NKG2D ligands.
In conclusion, it could be suggested that EGFR blockade is not the only action mechanism of EGFR inhibitors and effects of EGFR inhibitors can be extended to enhancement of immune recognition of cancer cells by NK cells. These observations raised the possibilities of priming cancer cells in vivo for NK cell-mediated lysis and combination of EGFR inhibitors and NK cell-based adoptive immunotherapy.
